Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Repare Therapeutics Inc. - Common Shares (NQ: RPTX )

1.320 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repare Therapeutics Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're diving into the biggest pre-market stock movers for Wednesday will a look at all of the latest news happening this morning. 
Via InvestorPlace
RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024
RPTX stock results show that Repare Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
From Debiopharm
Via Business Wire
Recap: Repare Therapeutics Q4 Earnings
Via Benzinga
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
From Repare Therapeutics Inc.
Via Business Wire
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx. 
Via Benzinga
Recap: Repare Therapeutics Q3 Earnings
Via Benzinga
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Repare Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
From Kirby McInerney LLP
Via Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
From Repare Therapeutics Inc.
Via Business Wire
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved. 
Via Benzinga
Repare Therapeutics to Regain Global Rights to Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
From Repare Therapeutics Inc.
Via Business Wire
These Biotech Stocks Could Double Your Money, According To Analysts
Via Benzinga
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
From Repare Therapeutics Inc.
Via Business Wire
$2.8M Bet On Repare Therapeutics? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.